HighGravityDataCurrent guidance
15 items
Halozyme Therapeutics
Guidance from Halozyme Therapeutics’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Aug 6, 2026
Data checked
Aug 6, 2026
What changed in the Aug 6, 2026 release
Each item compared with the same item in the previous release (May 11, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Raised | Revenue from royalties | for FY2026 | “$1.130 billion to $1.170 billion, representing growth of 30% to 35% over 2025” | “$1.220 billion to $1.245 billion, representing growth of 41% to 43% over 2025” | Filing ↗ |
| Raised | Royalty Revenue | for FY2026 | “$1.130 to $1.170 billion” | “$1.220 to $1.245 billion” | Filing ↗ |
| Raised | Total revenue | for FY2026 | “$1.710 billion to $1.810 billion, representing growth of 22% to 30% over 2025 total revenue” | “$1.835 billion to $1.910 billion, representing growth of 31% to 37% over 2025 total revenue” | Filing ↗ |
| Raised | Adjusted EBITDA | for FY2026 | “$1.125 billion to $1.205 billion, representing growth of 71% to 83% over 2025” | “$1.225 billion to $1.280 billion, representing growth of 86% to 95% over 2025” | Filing ↗ |
| Raised | Non-GAAP diluted earnings per share | for FY2026 | “$7.75 to $8.25, representing growth of 87% to 99% over 2025” | “$8.65 to $9.00, representing growth of 108% to 117% over 2025” | Filing ↗ |
| Raised | Non-GAAP Diluted EPS | for FY2026 | “$7.75 to $8.25” | “$8.65 to $9.00” | Filing ↗ |
Show 4 items not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | ENHANZE royalty revenue | for FY2026 | “exceed $1 billion” | — | Filing ↗ |
| Not restated | ENHANZE products in development | for FY2026 | “13” | — | Filing ↗ |
| Not restated | Goal of new SC delivery platform deals | for FY2026 | “three” | — | Filing ↗ |
| Not restated | New drug delivery licensing agreements signed | for FY2026 | “three or more” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| ENHANZE royalty revenue | “exceed $1 billion” | for FY2026 | GAAP-tied | May 11, 2026 | 1 | Filing ↗ |
| Revenue from royalties | “$1.220 billion to $1.245 billion, representing growth of 41% to 43% over 2025” | for FY2026 | GAAP-tied | Jan 28, 2026 | 3 | Filing ↗ |
| Royalty Revenue | “$1.220 to $1.245 billion” | for FY2026 | GAAP-tied | Jan 28, 2026 | 3 | Filing ↗ |
| Royalty Revenue Expected YoY Growth | “30% to 35%” | for FY2026 | GAAP-tied | Jan 28, 2026 | 1 | Filing ↗ |
| Total revenue | “$1.835 billion to $1.910 billion, representing growth of 31% to 37% over 2025 total revenue” | for FY2026 | GAAP-tied | Jan 28, 2026 | 3 | Filing ↗ |
| Total Revenue Expected YoY Growth | “23% to 30%” | for FY2026 | GAAP-tied | Jan 28, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA | “$1.225 billion to $1.280 billion, representing growth of 86% to 95% over 2025” | for FY2026 | Company-defined | Jan 28, 2026 | 3 | Filing ↗ |
| Hypercon and Surf Bio investment included in Adjusted EBITDA and EPS | “approximately $60 million” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Non-GAAP diluted earnings per share | “$8.65 to $9.00, representing growth of 108% to 117% over 2025” | for FY2026 | Company-defined | Jan 28, 2026 | 3 | Filing ↗ |
| Non-GAAP Diluted EPS | “$8.65 to $9.00” | for FY2026 | Company-defined | Jan 28, 2026 | 3 | Filing ↗ |
| ENHANZE products in development | “13” | for FY2026 | Company-defined | May 11, 2026 | 1 | Filing ↗ |
| Expected share repurchases | “at least $400 million of shares” | for FY2026 | Declared action | May 11, 2026 | 2 | Filing ↗ |
| Goal of new SC delivery platform deals | “three” | for FY2026 | Company-defined | May 11, 2026 | 1 | Filing ↗ |
| New drug delivery licensing agreements signed | “three or more” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| New Hypercon and Surf Bio investment included in | “approximately $60 million” | for FY2026 | Company-defined | May 11, 2026 | 1 | Filing ↗ |
| Partner programs in development | “15” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
Next year and medium term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Share repurchase program authorization | “up to $1.0 billion of its outstanding common stock” | for FY2028 | Declared action | May 11, 2026 | 2 | Filing ↗ |
No period stated
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| New Accelerated Share Repurchase (ASR) program | “$250 million” | — | Declared action | Jan 8, 2025 | 1 | Filing ↗ |
| Share repurchase | “$250 million” | — | Declared action | May 6, 2025 | 1 | Filing ↗ |
| Share repurchase program | “up to $1 billion” | — | Declared action | May 11, 2026 | 1 | Filing ↗ |
| Share repurchase tranche | “$250 million” | — | Declared action | Aug 5, 2025 | 1 | Filing ↗ |
How one item moved
Revenue from royalties, for FY2025 — every statement across the year, each linked to its filing.
Aug 5, 2025
Raised
“$825 million to $860 million, representing growth of 44% to 51% over 2024”
Nov 3, 2025
Raised
“$850 million to $880 million, representing growth of 49% to 54% over 2024”
How your Biopharma sector group guides
12 companies in Biopharma. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| BioMarin Pharmaceutical | Aug 6, 2026 | 19 changes |
| Halozyme Therapeutics | Aug 6, 2026 | 6 changes |
| Eli Lilly | Aug 5, 2026 | 5 changes |
| Amgen | Aug 4, 2026 | 5 changes |
| Gilead Sciences | Aug 4, 2026 | 15 changes |
| Moderna | Jul 31, 2026 | 8 changes |
| Neurocrine Biosciences | Jul 30, 2026 | 16 changes |
| Regeneron Pharmaceuticals | Jul 30, 2026 | 22 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2028 | FY2026 | FY2025 | FY2024 | No period |
|---|---|---|---|---|---|
| ENHANZE royalty revenue | — | 1 statement | — | — | — |
| Revenue from royalties | — | 3 statements | 4 statements | 1 statement | — |
| Royalty Revenue | — | 3 statements | 4 statements | 1 statement | — |
| Royalty Revenue Expected YoY Growth | — | 1 statement | — | — | — |
| Total revenue | — | 3 statements | 4 statements | 1 statement | — |
The full record for Halozyme Therapeutics and its Biopharma peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Aug 6, 2026 | FY2026 Q2 | 0001159036-26-000103 | 8 | Open filing ↗ |
| May 11, 2026 | FY2026 Q1 | 0001159036-26-000067 | 13 | Open filing ↗ |
| Jan 28, 2026 | FY2025 Q4 | 0001159036-26-000011 | 11 | Open filing ↗ |
| Nov 3, 2025 | FY2025 Q3 | 0001159036-25-000044 | 6 | Open filing ↗ |
| Aug 5, 2025 | FY2025 Q2 | 0001159036-25-000033 | 7 | Open filing ↗ |
| May 6, 2025 | FY2025 Q1 | 0001159036-25-000025 | 7 | Open filing ↗ |
| Jan 8, 2025 | FY2024 Q4 | 0001159036-25-000003 | 7 | Open filing ↗ |
| Oct 31, 2024 | FY2024 Q3 | 0001159036-24-000049 | 6 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error